.Pharmacolibrary.Drugs.ATC.J.J07CA12 .Pharmacolibrary.Drugs.ATC.J.J07CA12| name: | DiphtheriaPertussisPoliomyelitisTetanusHepatitisB |
| ATC code: | J07CA12 | route: | intramuscular |
| n-compartments | 1 |
This is a combination vaccine used to protect against five serious diseases: diphtheria, pertussis (whooping cough), poliomyelitis, tetanus, and hepatitis B. It is administered primarily to infants and young children as a part of routine immunization schedules. The vaccine is approved and widely used in pediatric practice worldwide.
No published pharmacokinetic studies or compartmental PK models are available for the pentavalent diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B combination vaccine. The vaccine is typically given as an intramuscular injection in infants and young children; classical pharmacokinetic parameters (such as systemic absorption rates, central volume of distribution, clearance) are not generally relevant or reported for vaccines.
Zhu, Q, et al., & Suzich, JA (2017). A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science translational medicine 9(388) –. DOI:10.1126/scitranslmed.aaj1928 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28469033
Maese, L, et al., & Rau, RE (2023). Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood 141(7) 704–712. DOI:10.1182/blood.2022016923 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36108304
Huang, CJ, et al., & Shih, KC (2023). Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study. European journal of drug metabolism and pharmacokinetics 48(6) 665–674. DOI:10.1007/s13318-023-00854-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37751056